Drug Profile
Clofarabine - Sanofi
Alternative Names: CAFdA; Cl-F-ara-A; Clofaribine; Clolar; Evoltra; GZ393590; JC0707; SAR 393590Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Southern Research Institute
- Developer Bioenvision; Dana-Farber Cancer Institute; Erasmus MC; Genzyme Oncology; Massachusetts General Hospital; Oncology Specialists S.C.; Sanofi; Sanofi Oncology; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University Hospital Southampton NHS Foundation Trust; University of California; University of Michigan Comprehensive Cancer Center; University of Utah; Yale University
- Class Antineoplastics; Antipsoriatics; Furans; Purine nucleosides; Small molecules
- Mechanism of Action Apoptosis stimulants; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Precursor cell lymphoblastic leukaemia-lymphoma
- Phase II Histiocytosis
- Phase I/II Haematological malignancies
- Preregistration Submission Withdrawal Acute myeloid leukaemia
- Discontinued B-cell lymphoma; Chronic lymphocytic leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Psoriasis; Solid tumours
Most Recent Events
- 13 Mar 2023 Massachusetts General Hospital completes a phase I/II trial in Non-Hodgkin's lymphoma (Second line therapy or greater) in the USA (PO) (NCT00644189)
- 27 Jul 2020 University of California in collaboration with Genzyme Sanofi terminates a phase-I/II clinical trials in Precursor cell lymphoblastic leukaemia-lymphoma (In adolescents, In children, In adults, Combination therapy, Second-line therapy or greater) in USA (IV), prior to July 2020 (NCT00983528)
- 28 Feb 2019 No recent reports of development identified for phase-I development in Precursor-cell-lymphoblastic-leukaemia-lymphoma(In children) in Unknown (PO)